REPH spins off BXRX—retaining only the CDMO business: https://www.globenewswire.com/news-release/2019/11/21/1951117/0/en/Recro-Completes-Separation-of-Baudax-Bio-and-Becomes-a-Dedicated-Contract-Development-and-Manufacturing-Organization.html Recro Pharma…today announced that it has completed the spin out of its Acute Care segment, Baudax Bio. Baudax Bio common stock will begin “regular way” trading on Friday, November 22, 2019, under the symbol “BXRX” on the Nasdaq Capital Market. Each REPH share will receive 0.4 shares of BXRX as a non-taxable distribution.